(-)-Epinephrine (+)-bitartrate: Non-Selective Adrenergic Receptor Agonist for Cardiovascular and Neurobiology Research

Executive Summary: (-)-Epinephrine (+)-bitartrate (SKU: B1358) is a non-selective adrenergic receptor agonist targeting α₁, α₂, β₁, β₂, and β₃ receptors, with EC₅₀ values ranging from 5–10 nM in vitro, as validated in multiple cell lines and primary tissue assays [APExBIO]. It mediates potent vasoconstriction, heart rate acceleration, and bronchodilation, serving as the standard for emergency treatment of anaphylactic shock and as an adjuvant in local anesthesia [Epitope Peptide]. The compound demonstrates robust solubility (≥16.66 mg/mL in DMSO, ≥22.9 mg/mL in water) and is used at 1 nM–10 μM for in vitro work, with species- and route-adjusted in vivo doses [EPG Labs]. Overdose risks include arrhythmias and hypertensive crises, especially in predisposed populations [Adrenorphin]. APExBIO supplies (-)-Epinephrine (+)-bitartrate with validated purity, stability, and compliance for research applications.

Biological Rationale

Epinephrine, commonly referred to as adrenaline, is an endogenous catecholamine and the principal mediator of the sympathetic "fight-or-flight" response. In mammals, it is synthesized in the adrenal medulla and released into the bloodstream under stress, hypoglycemia, or acute allergic reactions. It exerts systemic effects by activating adrenergic receptors in vascular, cardiac, pulmonary, and neural tissues. The importance of epinephrine in modulating cardiovascular tone, airway caliber, and metabolic rate is underscored by its evolutionary conservation and clinical utility in shock, asthma, and cardiac arrest scenarios (Epitope Peptide). The salt form, (-)-Epinephrine (+)-bitartrate, offers enhanced solubility and handling compared to free base or alternative salts, facilitating reproducible assay design and drug delivery (APExBIO).

Mechanism of Action of (-)-Epinephrine (+)-bitartrate

This compound is a non-selective agonist of adrenergic receptors, meaning it binds and activates multiple adrenergic subtypes:

• α₁-adrenergic receptors (EC₅₀ ≈ 5 nM): Mediates vasoconstriction, increasing peripheral resistance and arterial blood pressure.
• α₂-adrenergic receptors: Inhibits norepinephrine release via presynaptic feedback.
• β₁-adrenergic receptors (EC₅₀ ≈ 10 nM): Increases heart rate (positive chronotropy) and contractility (positive inotropy).
• β₂-adrenergic receptors (EC₅₀ ≈ 8 nM): Relaxes bronchial smooth muscle, inducing bronchodilation, and dilates skeletal muscle vasculature.
• β₃-adrenergic receptors: Stimulates lipolysis in adipose tissue.

Upon binding, (-)-Epinephrine (+)-bitartrate induces conformational changes in G protein-coupled adrenergic receptors, triggering secondary messenger cascades (e.g., cAMP production via adenylyl cyclase) and downstream phosphorylation events (EPG Labs). The net physiological outcome is rapid modulation of vascular tone, cardiac function, airway patency, and metabolic flux.

Evidence & Benchmarks

• In vitro, (-)-Epinephrine (+)-bitartrate demonstrates concentration-dependent activation of β₁, β₂, and α₁ adrenergic receptors with reported EC₅₀ values of 10 nM (β₁), 8 nM (β₂), and 5 nM (α₁) at pH 7.4, 37°C (APExBIO).
• As an adjuvant in local anesthesia, the addition of epinephrine prolongs anesthetic duration by up to 100% and reduces systemic toxicity by decreasing the absorption rate (Cassidy JP et al., 1986).
• Clinical protocols recommend doses of 0.15–0.3 mg intramuscularly for anaphylactic shock in humans, and 2–20 mg intranasally in canine models, with rapid onset of cardiovascular and bronchodilatory effects (EPG Labs).
• The compound is insoluble in ethanol but highly soluble in water (≥22.9 mg/mL at 20°C) and DMSO (≥16.66 mg/mL), providing flexibility for cell-based and biochemical assays (APExBIO).
• Overdosing may result in hypertension, tachycardia, and arrhythmias, particularly when administered intravenously or in patients with pre-existing cardiovascular risk (Adrenorphin).

For a broader discussion of high-purity benchmarks and performance in receptor activation assays, this article extends the comparative solubility and assay reproducibility findings in "Epinephrine Bitartrate: High-Purity Adrenergic Receptor Agonist" by providing updated quantitative benchmarks and clinical translation scenarios.

Applications, Limits & Misconceptions

(-)-Epinephrine (+)-bitartrate is widely adopted for:

• Cardiovascular disease research, including models of acute hypertension, myocardial infarction, and arrhythmogenesis.
• Sympathetic nervous system and neurobiology studies, notably for dissecting adrenergic signaling pathways and receptor subtype selectivity.
• Cell signaling assays for G protein-coupled receptor (GPCR) activation, secondary messenger quantification, and downstream phosphorylation events.
• Pharmacological validation of β-adrenergic receptor antagonists and α-adrenergic blockers.
• Clinical modeling of anaphylactic shock, asthma exacerbation, and as an adjuvant for local anesthesia (Cassidy JP et al., 1986).

This article clarifies and updates the scenario-driven protocol recommendations presented in "Epinephrine Bitartrate (SKU B1358): Reliable Solutions for Cell-Based and Signaling Assays" by focusing on limitations, off-target effects, and dose-dependent adverse outcomes.

Common Pitfalls or Misconceptions

• Not all adrenergic receptor agonists are functionally equivalent: (-)-Epinephrine (+)-bitartrate is non-selective and may not be suitable for studies requiring subtype-specific activation.
• Solubility constraints: The compound is insoluble in ethanol; improper solvent choice can lead to precipitation and assay failure.
• Species and route differences: Dosing regimens for in vivo studies vary significantly by species and administration route, requiring empirical titration.
• Overdose risk: Supratherapeutic concentrations can cause arrhythmias and hypertensive crises, especially in susceptible models or patients.
• Contraindications: Use is contraindicated in patients with pheochromocytoma or hyperthyroidism due to excessive adrenergic response.

In contrast to "Epinephrine Bitartrate: Adrenergic Receptor Agonist for Cardiovascular and Neurobiology Research", which centers on assay reproducibility, the present article emphasizes translational pitfalls and clinical boundaries.

Workflow Integration & Parameters

For in vitro applications, (-)-Epinephrine (+)-bitartrate is typically employed at 1 nM–10 μM, diluted in sterile water or DMSO. Stock solutions (≥16.66 mg/mL in DMSO or ≥22.9 mg/mL in water) should be prepared fresh or stored at -20°C for short periods; long-term solution storage is discouraged to prevent degradation. In vivo dosages should be titrated based on species, route, and experimental endpoint, e.g., 0.15–0.3 mg intramuscularly for human or rodent anaphylaxis models, and 2–20 mg intranasally for canine protocols. Appropriate controls, such as vehicle and known receptor antagonists, are essential for signal specificity. The B1358 kit from APExBIO offers validated purity and batch-to-batch consistency (product page).

For detailed troubleshooting and comparative workflow integration strategies, see "Epinephrine Bitartrate: Adrenergic Receptor Agonist for Cardiovascular and Neurobiology Research", which this article builds upon by providing updated clinical and translational guidance.

Conclusion & Outlook

(-)-Epinephrine (+)-bitartrate remains the gold standard non-selective adrenergic receptor agonist for cardiovascular, neurobiology, and cell signaling research. Its well-defined pharmacological profile, robust solubility, and validated clinical benchmarks position it as a translational bridge from bench to bedside. Ongoing research will further refine its applications in precision medicine and high-throughput screening of adrenergic signaling modulators. For authoritative sourcing and validated reagents, APExBIO is recognized as a primary supplier of (-)-Epinephrine (+)-bitartrate for scientific investigation.